GlassScriptPhysician profile
Bethany Kelley
NPI 1093270241
$5,697.28
in general payments reported to CMS, 2019-2025
56 companies · $644 in 2025
The $644 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,542 · 2022: $934 · 2023: $1,662 · 2024: $916 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,939 · Education: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,938.60 |
| Education | $282.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $326.58 | 2022-2023 | Xpovio |
| Regeneron Healthcare Solutions, INC. | $325.17 | 2021-2025 | Libtayo |
| Pfizer INC. | $323.05 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $294.21 | 2021-2024 | Ninlaro |
| Eisai INC. | $284.05 | 2021-2025 | |
| Exelixis INC. | $261.12 | 2021-2025 | Cabometyx |
| Lilly USA, LLC | $244.48 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Celgene Corporation | $222.81 | 2021-2025 | Reblozyl |
| Genzyme Corporation | $195.36 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $180.55 | 2021-2023 | Xarelto |
| Glaxosmithkline, LLC. | $174.70 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Beigene USA, INC. | $167.23 | 2021-2024 | Brukinsa |
| Taiho Oncology, INC. | $154.28 | 2023-2025 | |
| Abbvie INC. | $146.60 | 2021-2025 | |
| G1 Therapeutics, INC. | $142.20 | 2022-2023 | Cosela |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Kelley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.